Faculty Appointments
Patient Care Settings
Cancer, Obstetrics & Gynecology
Biography
I believe all patients should be treated with compassion, along with an individualized plan for their treatment and care utilizing a multidisciplinary team approach. We approach each of our patients with the philosophy of "What would you want done for your loved one?" (Quote from Cornelius "Skip" Granai, III, M.D.)
Gynecologic oncology is a unique subspecialty that provides for the participation in all parts of a patient's care. The opportunity to be involved in such a personal experience during a patient's life -- from the time of diagnosis through surgery to managing chemotherapy and participating in all aspects of a woman's care -- is an honor and privilege.
My areas of expertise include robotic surgery for ovarian, endometrial and cervical malignancies, as well as sentinel lymph node mapping for endometrial, cervical and vulvar malignancies, and ovarian cancer biomarker research for the early detection and management of ovarian cancer.
Conditions I Treat:
- Ovarian cancer
- Fallopian tube cancer
- Primary peritoneal cancer
- Endometrial cancer
- Cervical cancer
- Vaginal cancer
- Vulvar cancer
Professional Background
Richard G. Moore, M.D., FACOG, FACS, joined UR Medicine's Obstetrics and Gynecology as the Director of the Gynecologic Oncology Division on October 1, 2015. Dr. Moore will also lead Wilmot Cancer Institute's Gynecology Service Line and serve as Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers.
Dr. Moore comes to UR Medicine from Brown University and Women & Infants Hospital of Rhode Island. A native of Montreal, Quebec, Canada, Dr. Moore graduated from the University of Alberta Medical School in Edmonton. He completed his residency at Eastern Virginia Graduate School of Medicine, where he also served as Administrative Chief Resident. He completed a fellowship in Gynecologic Oncology and Breast Surgery at Women & Infants Hospital/Brown University. Dr. Moore joined the faculty at Women and Infants/Brown University after leaving fellowship. He served as the Associate Director of the Program in Women's Oncology since 2009 and was the Director of the Center for Biomarkers and Emerging Technology as well as the Molecular Therapeutics laboratory.
Dr. Moore is board-certified in gynecologic oncology and is a fellow of the American College of Obstetricians and Gynecologists and a fellow of the American College of Surgeons.
In addition to his clinical interest in ovarian and endometrial cancers, Dr. Moore is recognized internationally as a leading expert on the use of biomarkers to detect ovarian cancer. He led the team that developed the Risk of Ovarian Malignancy Algorithm (ROMA), a test that is cleared for use in Europe and Asia and was recently cleared by the U.S. Food and Drug Administration to detect ovarian cancer in women who have an ovarian cyst or pelvic mass.
Dr. Moore will see patients at 125 Lattimore Road, Suite 258 and will perform surgeries at Highland Hospital, which has been awarded the Gold Seal of Approval by the Joint Commission and leads the state in the number of minimally invasive, robotic surgeries for gynecologic cancer performed each year.
Credentials
Specialties
- Gynecologic Oncology - American Board of Obstetrics & Gynecology
- Obstetrics and Gynecology - American Board of Obstetrics & Gynecology
Education
1993
MD | University of Alberta School of Medicine (Canada)
Post-doctoral Training & Residency
07/01/1999 - 06/30/2002
Fellowship in Gynecologic Oncology at Brown University School of Medicine
07/01/1994 - 06/30/1997
Residency in Obstetrics and Gynecology at Eastern Virginia Medical School-GME
07/01/1993 - 06/30/1994
Internship in Obstetrics and Gynecology at Eastern Virginia Medical School-GME
VIEW ALL expand_more
Awards
2015
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2014 - 2014
New England Association of Gynecologic Oncologists
Sponsor: Basic Science Paper Award. Mentee: Elizabeth Lokich, MD. HE4 ex
Location: Newport RI,
2014
Rhode Island Monthly Journal, 2014
Sponsor: Rhode Island Top Doc
2013
AACC's Outstanding Speaker Award for 2013
Sponsor: American Association of clinical Chemists
2013
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2013
Rhode Island Monthly Journal, 2013
Sponsor: Rhode Island Top Doc
2012
Rhode Island Monthly Journal, 2012
Sponsor: Rhode Island Top Doc
2012
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2011
Providence Business News Innovation Awards 2011
Sponsor: For the "Artificial Ovary
Location: Brown University and Women and Infants Hospital
2011
Consumer's Research Council of America
Sponsor: Guide to America's Top Obstetricians and Gynecologists
2010
Time Magazine: Top ten Medical Breakthroughs for 2010
Sponsor: In vitro maturation of oocytes via the prefabricated self-assem
2008
New England Association of Gynecologic Oncologists
Sponsor: Comparison of a novel multiple biomarker assay to the risk of ma
Location: Cape Cod
2008
New England Association of Gynecologic Oncologists
Sponsor: Differential expression of CA125 and a novel serum tumor marker
Location: Cape Cod
2008
Full Time Faculty Excellence in Teaching Award
2008
Teaching Award from Chief Residents: Full Time Faculty
2007 - 2007
SGO Clinical Practice Science Poster Award
Sponsor: sentinel lymph node dissection alone with conservative ...
Location: San Diego, CA
2006
Medical Student Teaching Award
Sponsor: BioMed 351
Location: Brown University
2006
2006 Outstanding faculty mentorship award; from the resident graduating class of 2006
2005
New England Association of Gynecologic Oncology
Sponsor: Long term follow-up of patients with stage I and II vulvar ...
2002
New England Association of Gynecologic Oncologists
Sponsor: Sentinel node identification and the ability to detect ...
1997
The American Association of Gynecologic Laparoscopists Award
1996 - 1997
Resident of the Year
1996 - 1997
Administrative Chief Resident
1996
Gynecologic Oncology Resident Award
1996
Society of Assisted Reproductive Medicine Award
VIEW ALL expand_more
Clinical Trials
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women With Recurrent, Persistent or Metastatic Endometrial Cancer (NRG-GY012)
Lead Researcher: Richard G Moore
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Testing the combinations may lower the chance of endometrial cancer growing or spreading compared to usual care.
View Study Details
A Phase 3, Randomized, Double-Blind, Placebo/Paclitaxel-Controlled Study of Batiraxcept (AVB-S6-500) in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
Lead Researcher: Richard G Moore
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant recurrent ovarian cancer.
View Study Details
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Lead Researcher: Richard G Moore
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
View Study Details
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Lead Researcher: Richard G Moore
This trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for women with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.
View Study Details
NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Lead Researcher: Richard G Moore
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
View Study Details
EMBER2 Study:
Evaluation of multiple biomarkers to
estimate risk of cancer in gynecology
patients presenting with a pelvic mass (ANG-006)
Lead Researcher: Richard G Moore
The purpose of this study is to validate and refine a technology that can help physicians determine whether
an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test.
The specific technology is called ParsortixTM PC1 system, a semi-automated system capable of capturing and
harvesting rare cells for subsequent analysis from blood based on the size and deformability of the cells.
View Study Details
Patents
Patent Title: Therapy for Malignant Disease Comprising the Inhibition of Human Epididymal Secretory Protein E4 and Immune Checkpoint Inhibitors
Patent #: 2,981,068
Issue Date: Dec 14, 2021
Country: Canada
Invented By:
Richard G Moore, Rakesh K Singh, Naohiro Yano
Patent Title: Therapy for Malignant Disease
Patent #: 10,376,535
Issue Date: Aug 13, 2019
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh, Naohiro Yano
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: 3311165
Issue Date: Dec 09, 2020
Country: Europe
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: FR3311165
Issue Date: Dec 09, 2020
Country: France
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: DE3311165
Issue Date: Dec 09, 2020
Country: Germany
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Septin Proteins as Novel Biomarkers for Detection and Treatment of Mullerian Cancers
Patent #: GB3311165
Issue Date: Dec 09, 2020
Country: United Kingdom
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 11,034,719
Issue Date: Jun 15, 2021
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 3128996
Issue Date: Jun 02, 2021
Country: Europe
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: FR3128996
Issue Date: Jun 02, 2021
Country: France
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: DE3128996
Issue Date: Jun 02, 2021
Country: Germany
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: GB3128996
Issue Date: Jun 02, 2021
Country: United Kingdom
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 9,982,010
Issue Date: May 29, 2018
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
Patent Title: 7-Dehydrocholesterol Derivatives and Methods Using Same
Patent #: 10,683,324
Issue Date: Jun 16, 2020
Country: United States
Invented By:
Richard G Moore, Rakesh K Singh
VIEW ALL expand_more
Publications
Journal Articles
3/15/2022
Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, Cella D, Tew WP, Cloven NG, Muller CY, Bender DP, Moore RG, Michelin DP, Waggoner SE, Geller MA, Fujiwara K, D'Andre SD, Carney M, Alvarez Secord A, Moxley KM, Bookman MA. "Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 Mar 15; :JCO2102011. Epub 2022 Mar 15.
9/17/2021
Escandón JM, Bustos VP, Santamaría E, Langstein HN, Ciudad P, Hernandez-Alejandro R, Moore RG, Leckenby JI, Manrique OJ. "Evolution and Transformation of Uterine Transplantation: A Systematic Review of Surgical Techniques and Outcomes." Journal of reconstructive microsurgery.. 2021 Sep 17; Epub 2021 Sep 17.
4/26/2021
Rowswell-Turner RB, Singh RK, Urh A, Yano N, Kim KK, Khazan N, Pandita R, Sivagnanalingam U, Hovanesian V, James NE, Ribeiro JR, Kadambi S, Linehan DC, Moore RG. "HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression." The Journal of immunology : official journal of the American Association of Immunologists.. 2021 Apr 26; Epub 2021 Apr 26.
Books & Chapters
2011
Chapter Title: Breast Development and Anatomy
Book Title: Clinical Obstetrics and Gynecology
Author List: Sonali Pandya and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011
2011
Chapter Title: Management of Ovarian Cysts and Adnexal Masses
Book Title: Precis Gynecology
Author List: Richard G. Moore and Shannon MacLaughlan
Published By: Precis: Gynecology 2011
2011
Chapter Title: Forward
Book Title: Clinical Obstetrics and Gynecology,
Author List: James W. Orr and Richard G. Moore
Published By: Wolters Kluwer / Lippincott Williams & Wilkins 2011
VIEW ALL PUBLICATIONS